Navigation Links
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
Date:5/9/2008

HOPKINTON, Mass., May 9 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, May 15th, 2008 at 9:00am EDT to review the first quarter ending March 31, 2008 and discuss other matters related to the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

To access the conference call, please dial 877-795-3649 for domestic and 719-325-4817 international. The code for this conference call is 1073493. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Thursday, May 29th, 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres is a trademark and Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact:

Sharon Correia - 508-497-2360 ext. 224

Alseres Pharmaceuticals, Inc.

scorreia@alseres.com

Adam Friedman - 212-981-2529 ext. 18

Adam Friedman Associates

adam@adam-friedman.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
2. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
5. Vion Pharmaceuticals to Appeal Nasdaq Delisting
6. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
7. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
8. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
9. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... When an Au Pair comes all the ... what they are in for and they are often worried things won’t go well. More ... hoping for. This year’s Au Pair of the Year winner’s all commented how their Au ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical Therapy ... Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the country ... in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a ... the integration of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and ... intelligence (BI) to their small and medium business (SMB) clients. , ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one ... consists of physicians establishing, leading and partnering with ambulatory surgery centers across the United ... Center, also known as an ASC, is a modern health care facility focused on ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , February 12, 2016 ... anders vermerkt)   http://www.sedar.com ) ... http://www.telestatherapeutics.com abrufbar.    --> ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des zweiten ...
(Date:2/12/2016)... 2016  Sequent Medical, Inc. announced today that it ... the safety and effectiveness of the WEB™ Aneurysm Embolization ... aneurysms.  Prof Laurent Spelle , MD, Head of ... France and Principal Investigator of the CLARYS ... and Germany.  Although patients with ruptured aneurysms ...
Breaking Medicine Technology: